DK200500170A - Composition, method and kit for detecting antibodies to a human retrovirus in vitro - Google Patents

Composition, method and kit for detecting antibodies to a human retrovirus in vitro Download PDF

Info

Publication number
DK200500170A
DK200500170A DK200500170A DKPA200500170A DK200500170A DK 200500170 A DK200500170 A DK 200500170A DK 200500170 A DK200500170 A DK 200500170A DK PA200500170 A DKPA200500170 A DK PA200500170A DK 200500170 A DK200500170 A DK 200500170A
Authority
DK
Denmark
Prior art keywords
hiv
vitro
antibodies
composition
human
Prior art date
Application number
DK200500170A
Other languages
Danish (da)
Inventor
Montagnier Luc
Chamaret Solange
Guetard Denise
Alizon Marc
Clavel Francois
Guyader Mireille
Sonigo Pierre
Brun-Vezinet Francoise
Rey Marianne
Rouzioux Christine
Katlama Christine
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27576220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200500170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8600910A external-priority patent/FR2593189B1/en
Priority claimed from FR8600911A external-priority patent/FR2593190B1/en
Priority claimed from FR8601635A external-priority patent/FR2593922B1/en
Priority claimed from FR8601985A external-priority patent/FR2594229B1/en
Priority claimed from US06/835,228 external-priority patent/US4839288A/en
Priority claimed from FR8603881A external-priority patent/FR2596063B1/en
Priority claimed from FR8604215A external-priority patent/FR2597500B1/en
Publication of DK200500170A publication Critical patent/DK200500170A/en
Priority to DK200500170A priority Critical patent/DK176253B1/en
Application filed by Pasteur Institut filed Critical Pasteur Institut
Priority to DK200600325A priority patent/DK200600325A/en
Publication of DK176253B1 publication Critical patent/DK176253B1/en
Application granted granted Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)

Description

Patentkrav 1. Præparat tif in vitro påvisning af tilstedeværelsen i en biologisk prøve af antistoffer mod et humant retrovirus, der er i stand til at have cytopatogen virkning på humane T4 lymfocytter, omfattende mindst et HIV-1 antigen, kendetegnet ved, at det yderligere omfatter mindst et HIV-2 antigen der genkendes af antistofferne, der fremkaldes mod de tilsvarende antigener af et vilkårligt af de i CNCM deponerede HIV-2 retrovirus med numrene I- 502, I-532, I-642 og I-643 eller i ECACC deponerede HIV-2 retrovirus med numrene 87.011001 og 87.011002 {svarende til henholdsvis I-502 og I-532) eller en variant af en af disse HIV-2 retrovirus, 2. Præparat ifølge krav 1,kendetegnet ved, at det omfatter et gly¬ coprotein af HIV-2 retrovirus. 3. Præparat ifølge krav 1, kendetegnet ved, at det omfatter et HIV-2 p12 protein, der genkendes immunologisk af antistoffer fremkaldt mod de deponerede HIV-2 retrovira og har en molekylvægt i størrelsesordenen 12.000 daltons. 4. Præparat ifølge ethvert af kravene 1 til 3, kendetegnet ved, at det omfatter kerneproteiner fra HIV-1 og fra HIV-2. 5. Præparat ifølge krav 4, kendetegnet ved, at det omfatter p25 fra HIV-1 og p26 fra HIV-2. 6. Præparat ifølge krav 4, kendetegnet ved, at det omfatter p18 fra HIV-1 og p16 fra HIV-2. 7. Præparat ifølge krav 1,kendetegnet ved, at det inde omfatter holder omhylningsglycoproteiner fra HIV-1 og omhylningsglycoproteiner fra HIV-2. 8. Præparat ifølge krav 7, kendetegnet ved, at det omfatter gp110 fra HIV-1 og gp140 fra HIV-2. 9. Præparat ifølge krav 7 eller 8, kendetegnet ved, at det omfatter p42 fra HIV-1 og p36 fra HIV-2. 10. Præparat ifølge krav 1,kendetegnet ved, at det indeholder blan¬ dinger af antigeniske proteiner og/eller glycoproteiner fra HIV-1, og/eller blandinger af proteiner og/eller glycoproteiner fra HIV-2. 11. Fremgangsmåde til in vitro påvisning i en human biologisk prøve, f.eks. et serum, af tilstedeværelsen af antistoffer, der genkender antigener fra et hu¬ mant retrovirus, der er i stand til at have cytopatogen virkning på de humane T4 lymfocyter, og specielt til in vitro diagnose af en potentiel eller eksisteren¬ de LAS eller AIDS, der er forårsaget af et humant retrovirus, kendetegn e t ved, at man bringer den biologiske prøve fra den person, der skal diag¬ nosticeres, i kontakt med en blanding af antigener, der er i stand til at give en specifik immunologisk reaktion med antistofferne mod et humant HIV-1 retro¬ virus, eller mod et humant HIV-2 retrovirus, der er i stand til at have en cytopatogen virkning, og som genkendes af antistofferne, der fremkaldes mod de tilsvarende antigener af et vilkårligt af de i CNCM deponerede HIV-2 retrovirus med numrene I-502, I-532, I-642 og I-643 eller i ECACC depone¬ rede HIV-2 retrovirus med numrene 87.011001 og 87.011002 (svarende til henholdsvis I-502 og I-532), eller en variant af en af disse HIV-2 retrovira, og at man påviser et muligt dannet immunologisk konjugat mellem mindst et af disse antigener og antistofferne. 12. Fremgangsmåde ifølge krav 11,kendetegnet ved, at man bringer den biologiske prøve fra den person, som skal diagnosticeres, i kontakt med en blanding af antigener fra både et HIV-1 og et HIV-2 retrovirus, hvilket anti- gen fra HIV-2 genkendes af antistofferne, der fremkaldes mod de tilsvarende antigener af et vilkårligt af de i CNCM deponerede HIV-2 retrovirus med num¬ rene 1-502, 1-532, 1-642 og 1-643 eller i ECACC deponerede HIV-2 retrovirus med numrene 87.011001 og 87.011002 (svarende til henholdsvis I-502 og I- 532) eller en variant af en af disse HIV-2 retrovirus, specielt med et præparat ifølge et vilkårligt af kravene 1-8, og at man påviser det muligt dannede im¬ munologiske konjugat mellem mindst et af disse antigener og antistofferne. 13. Kit til in vitro påvisning af tilstedeværelse af antistoffer mod et retrovirus, der er cytopatogent for humane T4 lymfocyter, specielt hos en person, der muligvis bærer disse antistoffer, kendetegnet ved, at det omfatter en blanding af mindst et HIV-1 antigen og mindst et HIV-2 antigen, specielt et præparat som defineret i et vilkårligt af kravene 1-8; midler til påvisning af et immunologisk konjugat, der resulterer af den immunologiske reaktion mellem antigenerne og antistofferne i den biologiske væske.Patent claim 1. Preparation for in vitro detection of the presence in a biological sample of antibodies to a human retrovirus capable of having cytopathogenic effect on human T4 lymphocytes comprising at least one HIV-1 antigen, characterized in that it further comprises at least one HIV-2 antigen recognized by the antibodies raised against the corresponding antigens of any of the HIV-2 retroviruses deposited in CNCM with numbers I-502, I-532, I-642 and I-643 or ECACC deposited HIV-2 retroviruses having the numbers 87.011001 and 87.011002 (corresponding to I-502 and I-532, respectively) or a variant of one of these HIV-2 retroviruses, 2. A composition according to claim 1, characterized in that it comprises a glycoprotein of HIV-2 retroviruses. Composition according to claim 1, characterized in that it comprises an HIV-2 p12 protein that is immunologically recognized by antibodies raised against the deposited HIV-2 retroviruses and has a molecular weight of the order of 12,000 daltons. Composition according to any one of claims 1 to 3, characterized in that it comprises core proteins from HIV-1 and from HIV-2. Composition according to claim 4, characterized in that it comprises p25 from HIV-1 and p26 from HIV-2. Composition according to claim 4, characterized in that it comprises p18 from HIV-1 and p16 from HIV-2. A composition according to claim 1, characterized in that it comprises envelope glycoproteins of HIV-1 and envelope glycoproteins of HIV-2. Composition according to claim 7, characterized in that it comprises gp110 from HIV-1 and gp140 from HIV-2. Composition according to claim 7 or 8, characterized in that it comprises p42 from HIV-1 and p36 from HIV-2. Composition according to claim 1, characterized in that it contains mixtures of antigenic proteins and / or glycoproteins from HIV-1, and / or mixtures of proteins and / or glycoproteins from HIV-2. A method for in vitro detection in a human biological sample, e.g. a serum, from the presence of antibodies recognizing antigens from a human retrovirus capable of cytopathogenic action on human T4 lymphocytes, and in particular for in vitro diagnosis of a potential or existing LAS or AIDS, caused by a human retrovirus, characterized by contacting the biological sample of the person to be diagnosed with a mixture of antigens capable of producing a specific immunological reaction with the antibodies against a human HIV-1 retrovirus, or against a human HIV-2 retrovirus capable of having a cytopathogenic effect, which is recognized by the antibodies raised against the corresponding antigens by any of the HIV deposited in CNCM -2 retroviruses with numbers I-502, I-532, I-642 and I-643 or in the ECACC, HIV-2 retroviruses were deposited with numbers 87.011001 and 87.011002 (corresponding to I-502 and I-532 respectively), or variant of one of these HIV-2 retrovi ra, and that a possible immunological conjugate formed between at least one of these antigens and the antibodies is detected. A method according to claim 11, characterized in that the biological sample of the subject to be diagnosed is contacted with a mixture of antigens from both an HIV-1 and an HIV-2 retrovirus, which antigen from HIV. -2 is recognized by the antibodies raised against the corresponding antigens by any of the HIV-2 retroviruses deposited in CNCM with numbers 1-502, 1-532, 1-642 and 1-643 or HIV-2 deposited in ECACC retroviruses having the numbers 87.011001 and 87.011002 (corresponding to I-502 and I-532, respectively) or a variant of one of these HIV-2 retroviruses, especially with a composition according to any one of claims 1-8, and demonstrating the possible immunological conjugate between at least one of these antigens and the antibodies. An in vitro detection kit for the presence of antibodies to a retrovirus cytopathogenic for human T4 lymphocytes, especially in a person possibly carrying these antibodies, characterized in that it comprises a mixture of at least one HIV-1 antigen and at least one HIV-2 antigen, especially a composition as defined in any one of claims 1-8; means for detecting an immunological conjugate resulting from the immunological reaction between the antigens and antibodies in the biological fluid.

DK200500170A 1986-01-22 2005-02-04 New type of human immuno-deficiency virus, infections for T4 cells - and derived antigens, immunogens, monoclonal antibodies and nucleic acid sequences, e.g. for diagnosis of AIDS DK176253B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK200500170A DK176253B1 (en) 1986-01-22 2005-02-04 New type of human immuno-deficiency virus, infections for T4 cells - and derived antigens, immunogens, monoclonal antibodies and nucleic acid sequences, e.g. for diagnosis of AIDS
DK200600325A DK200600325A (en) 1986-01-22 2006-03-06 Method for in vitro detection of an HIV-2 retrovirus

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
FR8600910 1986-01-22
FR8600910A FR2593189B1 (en) 1986-01-22 1986-01-22 NEW RETROVIRUS THAT MAY CAUSE AIDS, ANTIGENS OBTAINED FROM THIS RETROVIRUS AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
FR8600911 1986-01-22
FR8600911A FR2593190B1 (en) 1986-01-22 1986-01-22 NEW RETROVIRUS THAT MAY CAUSE AIDS, ANTIGENS OBTAINED FROM THIS RETROVIRUS AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
FR8601635 1986-02-06
FR8601635A FR2593922B1 (en) 1986-02-06 1986-02-06 NEW RETROVIRUS THAT MAY CAUSE AIDS, ANTIGENS OBTAINED FROM THIS RETROVIRUS AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
FR8601985A FR2594229B1 (en) 1986-02-13 1986-02-13 NEW LAV-II TYPE RETROVIRUS LIKELY TO CAUSE AIDS, ANTIGENS OBTAINED THEREFROM AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
FR8601985 1986-02-13
US06/835,228 US4839288A (en) 1986-01-22 1986-03-03 Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US83522886 1986-03-03
FR8603881 1986-03-18
FR8603881A FR2596063B1 (en) 1986-03-18 1986-03-18 NEW RETROVIRUS THAT MAY CAUSE AIDS, ANTIGENS OBTAINED FROM THIS RETROVIRUS AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
FR8604215A FR2597500B1 (en) 1986-03-24 1986-03-24 NEW RETROVIRUS THAT MAY CAUSE AIDS, ANTIGENS OBTAINED FROM THIS RETROVIRUS AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
FR8604215 1986-03-24
US91608086A 1986-10-06 1986-10-06
US91608086 1986-10-06
US93318486A 1986-11-21 1986-11-21
US93318486 1986-11-21
DK493487 1987-09-21
DK198704934A DK175959B1 (en) 1986-01-22 1987-09-21 Human HIV-2 retrovirus that can cause AIDS, and method and means for detecting this retrovirus in vitro
DK200500170 2005-02-04
DK200500170A DK176253B1 (en) 1986-01-22 2005-02-04 New type of human immuno-deficiency virus, infections for T4 cells - and derived antigens, immunogens, monoclonal antibodies and nucleic acid sequences, e.g. for diagnosis of AIDS

Publications (2)

Publication Number Publication Date
DK200500170A true DK200500170A (en) 2005-02-04
DK176253B1 DK176253B1 (en) 2007-04-30

Family

ID=27576220

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198704934A DK175959B1 (en) 1986-01-22 1987-09-21 Human HIV-2 retrovirus that can cause AIDS, and method and means for detecting this retrovirus in vitro
DK200500170A DK176253B1 (en) 1986-01-22 2005-02-04 New type of human immuno-deficiency virus, infections for T4 cells - and derived antigens, immunogens, monoclonal antibodies and nucleic acid sequences, e.g. for diagnosis of AIDS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK198704934A DK175959B1 (en) 1986-01-22 1987-09-21 Human HIV-2 retrovirus that can cause AIDS, and method and means for detecting this retrovirus in vitro

Country Status (15)

Country Link
EP (2) EP0239425B1 (en)
JP (7) JP2611106B2 (en)
AR (1) AR243931A1 (en)
AT (2) ATE47725T1 (en)
AU (1) AU601397B2 (en)
DE (3) DE3760912D1 (en)
DK (2) DK175959B1 (en)
ES (1) ES2150897T3 (en)
GR (3) GR880300056T1 (en)
HK (1) HK62091A (en)
NZ (1) NZ219024A (en)
OA (1) OA08468A (en)
PT (1) PT84182B (en)
SG (1) SG28591G (en)
WO (1) WO1987004459A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002892A1 (en) * 1985-11-14 1987-05-21 President And Fellows Of Harvard College T-lymphotrophic virus
ATE154808T1 (en) * 1987-01-16 1997-07-15 Pasteur Institut PEPTIDES WITH THE IMMUNOLOGICAL PROPERTIES OF HIV-2
DE3856595D1 (en) * 1987-01-16 2009-01-22 Pasteur Institut HIV-2 and SIV-1 nucleotide sequences
NZ223980A (en) * 1987-03-23 1991-02-26 Hiver Ltd An aids-type virus vaccine comprising an antibody equivalent which recognises an epitope on a cd4 cell-marker
SE8701765L (en) * 1987-04-28 1988-10-29 Statens Bakteriologiska Lab METHOD OF ANALYSIS AND AGENTS FOR THIS
US4812556A (en) * 1987-05-18 1989-03-14 Virovahl Synthetic peptide antigen for the detection of HIV-2 infection
FR2620030B1 (en) * 1987-09-07 1990-03-23 Transgene Sa VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED
DE3879881D1 (en) * 1987-11-16 1993-05-06 Hoffmann La Roche RECOMBINANT HIV-2 POLYPEPTIDE.
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
WO1989006276A2 (en) * 1988-01-08 1989-07-13 Dpz Deutsches Primatenzentrum Gesellschaft Mbh Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
US6210874B1 (en) 1988-01-27 2001-04-03 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
WO1989009815A1 (en) * 1988-04-04 1989-10-19 Research Corporation Technologies, Inc. Novel virus of the hiv-2 family and methods of detection therefor
US5208321A (en) 1988-06-09 1993-05-04 Institut Pasteur HIV-2 transmembrane glycoprotein homodimer (GP 80)
EP1369427A3 (en) * 1988-06-09 2004-05-12 Innogenetics N.V. HIV-3 retrovirus strains and their use
US6197496B1 (en) 1988-06-09 2001-03-06 Institut Pasteur Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80
EP0345559A3 (en) * 1988-06-10 1990-07-11 Abbott Laboratories Hiv-2 variants
ES2194029T5 (en) † 1988-06-14 2016-10-26 Qiagen Gmbh HIV-2 virus variants
ES2085908T3 (en) * 1989-05-12 1996-06-16 Pasteur Institut ANTIGENS OF THE TRANSMEMBRANIC GLUCOPROTEIN COVER OF A HUMAN RETROVIRUS OF THE HIV-2 TYPE (ANTIGENS THAT HAVE AN IMMUNOLOGICAL RELATIONSHIP BETWEEN THEM).
FR2646854A1 (en) * 1989-05-12 1990-11-16 Pasteur Institut Antigens of the envelope transmembrane glycoprotein of a HIV-2 type human retrovirus, antigens exhibiting an immunological relationship with them
EP0400245B1 (en) * 1989-05-31 1995-12-20 Institut Pasteur Proteins and glycoproteins of the HIV-2 EHO retrovirus antibodies directed against them - application for the diagnosis
FR2647809B1 (en) * 1989-06-02 1991-09-20 Pasteur Institut OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-1, HIV-2 AND SIV RETROVIRUSES AND THEIR APPLICATIONS TO IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES
FR2647810B1 (en) * 1989-06-02 1994-07-22 Pasteur Institut OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-2 AND SIV RETROVIRUSES, AND THEIR APPLICATIONS TO THE IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES
EP0806484B1 (en) 1989-06-02 2006-04-12 Institut Pasteur Synthesis of proteins or polypeptides encoded by a sequence of HIV-1, HIV-2 or SIV.
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
ATE164853T1 (en) * 1990-01-16 1998-04-15 Orgenics Ltd PEPTIDES DERIVED FROM VIRUS HIV ENVEL GLYCOPROTEINS, THEIR USE FOR DETECTING INFECTION OF THESE VIRUSES AND FOR VACCINATION AGAINST AIDS
FR2657016B1 (en) * 1990-01-16 1995-08-25 Clonatec Sa PEPTIDES DERIVED FROM THE GLYCOPROTEIN ENVELOPE OF THE HIV-2 VIRUS, THEIR APPLICATIONS FOR THE DETECTION OF AN INFECTION DUE TO THIS VIRUS AND FOR VACCINATION AGAINST AIDS.
ES2053014T5 (en) 1990-06-15 2001-02-16 Innogenetics Nv THE RETROVIRUS SIVCPZ-ANT AND ITS USES.
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
CA2107732C (en) * 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
DE4233646C2 (en) * 1992-10-06 2003-10-23 Dade Behring Marburg Gmbh Retrovirus from the HIV group and its use
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
US5962665A (en) * 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
FR2767337B1 (en) 1997-08-14 2002-07-05 Pasteur Institut NUCLEIC SEQUENCES OF POLYPEPTIDES EXPORTED FROM MYCOBACTERI ES, VECTORS COMPRISING THEM AND APPLICATIONS TO DIAGNOSIS AND THE PREVENTION OF TUBERCULOSIS
AU3054502A (en) 2000-10-23 2002-05-06 Gen Probe Inc Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
CA2547750C (en) 2003-12-19 2014-04-08 Gen-Probe Incorporated Compositions, methods and kits for detecting the nucleic acids of hiv-1 and hiv-2
JP6721772B1 (en) 2019-03-26 2020-07-15 斉藤　幹雄 Cleaning device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652599A (en) * 1984-04-23 1987-03-24 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS using permissive cells
DE3587181T2 (en) * 1984-10-18 1993-06-24 Centre Nat Rech Scient F ANTIGENS OF THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR USE.
US4600413A (en) * 1984-12-10 1986-07-15 Sundstrand Corporation Centrifugal deaerator and pump
JP3105581B2 (en) * 1991-07-03 2000-11-06 内橋エステック株式会社 Planar temperature fuse

Also Published As

Publication number Publication date
OA08468A (en) 1988-07-29
DK493487A (en) 1987-11-17
JP2611106B2 (en) 1997-05-21
GR3034708T3 (en) 2001-01-31
JP2735521B2 (en) 1998-04-02
JPH06113833A (en) 1994-04-26
DE3752319T2 (en) 2001-03-15
EP0239425B1 (en) 1989-11-02
AU6891187A (en) 1987-08-14
EP0239425A1 (en) 1987-09-30
ES2150897T3 (en) 2000-12-16
SG28591G (en) 1993-02-19
DK493487D0 (en) 1987-09-21
HK62091A (en) 1991-08-16
DE3760912D1 (en) 1989-12-07
DK176253B1 (en) 2007-04-30
JPH07233196A (en) 1995-09-05
PT84182B (en) 1989-09-14
JPH08275783A (en) 1996-10-22
PT84182A (en) 1987-02-01
WO1987004459A1 (en) 1987-07-30
DE3752319D1 (en) 2000-09-07
JP2931294B2 (en) 1999-08-09
AR243931A1 (en) 1993-09-30
GR880300056T1 (en) 1988-10-18
JPH0975092A (en) 1997-03-25
JPH1118768A (en) 1999-01-26
JP2801162B2 (en) 1998-09-21
JPH08113598A (en) 1996-05-07
DE239425T1 (en) 1988-06-30
GR3001096T3 (en) 1992-04-17
JP2771519B2 (en) 1998-07-02
JPH0937778A (en) 1997-02-10
EP0320495A1 (en) 1989-06-14
ATE195148T1 (en) 2000-08-15
JP2874846B2 (en) 1999-03-24
EP0320495B1 (en) 2000-08-02
DK175959B1 (en) 2005-08-29
NZ219024A (en) 1990-04-26
ATE47725T1 (en) 1989-11-15
AU601397B2 (en) 1990-09-13

Similar Documents

Publication Publication Date Title
DK200500170A (en) Composition, method and kit for detecting antibodies to a human retrovirus in vitro
Salahuddin et al. HTLV-III in symptom-free seronegative persons
Hauser et al. Analysis of human T-lymphotropic virus sequences in multiple sclerosis tissue
EP0655501B2 (en) HIV-2 virus variants
Reiss et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1
BRPI0210598B8 (en) processes for producing a soluble complex comprising a target amyloidogenic protein and a peptidyl prolyl isomerase chaperone, for producing a soluble chaperone surface retroviral glycoprotein complex, and for detecting at least one antibody to a retroviral glycoprotein of surface in a sample, as well as soluble complex, and composition
EA200100943A1 (en) HIV PEPTIDES, ANTIGENS, VACCINE COMPOSITIONS, KIT FOR IMMUNO ANALYSIS AND METHOD FOR DETERMINING HIV-INDUCED ANTIBODIES
Archibald et al. Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection
CN1954217B (en) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an HIV virus in an individual
Ketema et al. Assessment of the performance of a rapid, lateral flow assay for the detection of antibodies to HIV
Irwin et al. Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America
Chou et al. Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs
US5019510A (en) Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
ES2058259T5 (en) SYNTHETIC ANTIGENS FOR THE DETECTION OF AIDS-RELATED DISEASE CAUSED BY LAV-2.
Pepose et al. Screening cornea donors for antibodies against human immunodeficiency virus: efficacy of ELISA testing of cadaveric sera and aqueous humor
Kline et al. Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay
Kline et al. Diagnosis and differentiation of HIV-1 and HIV-2 infection by two rapid assays in Nigeria
Bahraoui et al. Relevance of anti-nef antibody detection as an early serologic marker of human immunodeficiency virus infection
Cot et al. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis
Vallari et al. Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2
Montagnier Origin and evolution of HIVs and their role in AIDS pathogenesis
Barrett et al. Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood
Massanga et al. A highly heterogeneous HIV-1 epidemic in the Central African Republic.
Huisman et al. Detection of early anti-p24 HIV responses in EIA-and immunoblot-negative individuals
Delaporte et al. Interpretation of antibodies reacting solely with human retroviral core proteins in western equatorial Africa

Legal Events

Date Code Title Description
PUP Patent expired

Expiry date: 20250204